Prolonged survival after bevacizumab rechallenge in glioblastoma patients with previous response to bevacizumab†

Neuro-oncology Practice
Carmen BalañàAndrés Felipe Cardona

Abstract

The use of bevacizumab for recurrent glioblastoma is controversial. Here we show data on patients who responded to bevacizumab, then stopped bevacizumab for any reason other than progression and were rechallenged with bevacizumab at the time of subsequent progression. This retrospective study included 28 patients, classified in 2 cohorts: those for whom the first exposure to bevacizumab (BEV-1) was first-line treatment for newly diagnosed glioblastoma (Bev-F; N = 12) and those for whom BEV-1 was second- or third-line treatment for recurrent disease after standard treatment (Bev-S; N = 16). All patients received standard radiotherapy plus temozolomide. Bev-F patients also received concomitant bevacizumab. All 28 patients received a total of 57 treatment lines with bevacizumab (12 first-line and 45 second- or further-line). Twenty-nine lines were rechallenges (BEV-2 [N = 26] or BEV-3 [N = 3]). Objective response to rechallenge was 58.6% and clinical benefit was 89.6%. Overall survival (OS) was 55 months for RPA class IV and 26.7 months for RPA class V patients (P = .01). OS was 26.7 months for Bev-F patients and 52.1 months for Bev-S patients (P = .004). Post-progression survival was 20 months for Bev-F patients and 39.6 months f...Continue Reading

References

Jul 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D R MacdonaldJ G Cairncross
Jun 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·René-Olivier MirimanoffRoger Stupp
Oct 4, 2006·The Journal of Clinical Investigation·Michael R MancusoDonald M McDonald
Sep 6, 2007·Brain : a Journal of Neurology·Dietmar KrexUNKNOWN German Glioma Network
Jan 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sith SathornsumeteeJeremy N Rich
Dec 31, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Teri N KreislHoward A Fine
Apr 1, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Walid S KamounRakesh K Jain
Sep 2, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Henry S FriedmanTimothy Cloughesy
Oct 15, 2009·Nature Reviews. Neurology·Andrew D NordenPatrick Y Wen
Mar 17, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Patrick Y WenSusan M Chang
Mar 30, 2011·Annals of Neurology·Antje WickWolfgang Wick
May 12, 2011·Neuro-oncology·Jeffrey S WefelHenry S Friedman
May 31, 2012·Journal of Neuro-oncology·Birgit FlechlChristine Marosi
Oct 16, 2012·Journal of Neuro-oncology·Wendy J ShermanSean A Grimm
Nov 22, 2012·The Lancet Oncology·Jaafar BennounaUNKNOWN ML18147 Study Investigators
Jan 12, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Arman JahangiriManish K Aghi
Jan 29, 2013·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·Nicolas R SmollOliver P Gautschi
Jun 12, 2013·CNS Oncology·Kan V Lu, Gabriele Bergers
Jun 28, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yuji PiaoJohn F de Groot
Dec 12, 2013·Cancer Research·Arman JahangiriW Shawn Carbonell
Feb 21, 2014·The New England Journal of Medicine·Mark R GilbertMinesh P Mehta
Feb 21, 2014·The New England Journal of Medicine·Olivier L ChinotTimothy Cloughesy
Mar 7, 2014·Neuro-oncology·Mark D AndersonVinay K Puduvalli
Mar 13, 2014·International Journal of Cancer. Journal International Du Cancer·Guido ReifenbergerUNKNOWN German Glioma Network
May 16, 2014·Neuro-oncology·Roger Stupp, Michael Weller
Jun 21, 2014·Future Oncology·Alba A BrandesAntoine F Carpentier
Nov 2, 2014·Neuro-oncology·David SchiffPatrick Y Wen
Jul 1, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas SandmannCarlos Bais

❮ Previous
Next ❯

Citations

Apr 27, 2018·The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutica·Alessia PellerinoRoberta Rudà
Oct 28, 2018·International Journal of Molecular Sciences·Puja Sharma, Waldemar Debinski

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Stem Cells in Glioblastoma

Glioblastoma is the most common and aggressive type of brain tumor. It contains a population of tumor initiating stem cell-like cells known as cancer stem cells. Investigations are ongoing into these cancer stem cells found in these solid tumors which are highly resistance to treatment. Here is the latest research on cancer stem cells in glioblastoma.